SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05130385` - High Resolution Optical Coherence Tomography
Recruiting	`NCT04545736` - Oral Metformin for Treatment of ABCA4 Retinopathy	Phase 1/Phase 2
Completed	`NCT05820100` - Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT

See also

Status

Clinical Trial

Phase

Recruiting

NCT05130385 - High Resolution Optical Coherence Tomography

Recruiting

NCT04545736 - Oral Metformin for Treatment of ABCA4 Retinopathy

Phase 1/Phase 2

Completed

NCT05820100 - Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05902962
Study type	Interventional
Source	PYC Therapeutics
Contact	Ora Inc
Phone	1-510-423-2680
Email	VP001@oraclinical.com
Status	Recruiting
Phase	Phase 1
Start date	April 20, 2023
Completion date	April 30, 2024

SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects — Platypus

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms